CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 44 enrolled
Drug / intervention
Dexmedetomidine 0.7 Mcg/kg/hdrug
Likely dose
Dexmedetomidine 0.7 Mcg/kg/hfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02270281
NCT02270281Phase 4Completed
CompareCT.gov

Dexmedetomidine Improve Microcirculatory Alterations in Initial Resuscitated Septic Shock Patients

Southeast University, China·interventional·Posted Oct 21, 2014·Updated Dec 12, 2018

In Brief

A Phase 4 clinical trial evaluating Dexmedetomidine 0.7 Mcg/kg/h for Septic Shock. Completed, enrolled 44 participants across 1 site.

Detailed Summary

Dexmedetomidine was found might be beneficial to sepsis. Dexmedetomidine were found to improve microcirculation in sepsis animal studies and non-sepsis patients. However, the effect of dexmedetomidine on microcirculation in septic shock patients is unknown.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeptic Shock
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 21, 2014
Enrollment StartDec 1, 2014
Primary CompletionDec 1, 2016
Study CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 11.7 years ago

Interventions

Dexmedetomidine 0.7 Mcg/kg/hdrug

CIF 0.7mcg/kg/h